JP Morgan Chase
SGMT icon

JP Morgan Chase’s Sagimet Biosciences SGMT Stock Holding History

JP Morgan Chase’s Portfolio SGMT Stock Details SGMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$225K Buy
28,930
+26,612
+1,148% +$181K ﹤0.01% 5555
2026
Q1 		$10.5K Sell
2,318
-170
-7% -$947 ﹤0.01% 6729
2025
Q4 		$14.7K Buy
2,488
+2,390
+2,439% +$17.2K ﹤0.01% 6580
2025
Q3 		$672 Hold
98
– – ﹤0.01% 7031
2025
Q2 		$747 Hold
98
– – ﹤0.01% 6655
2025
Q1 		$319 Sell
98
-47,966
-100% -$201K ﹤0.01% 6746
2024
Q4 		$216K Sell
48,064
-23,953
-33% -$121K ﹤0.01% 5441
2024
Q3 		$199K Buy
72,017
+28,690
+66% +$88.4K ﹤0.01% 5406
2024
Q2 		$148K Sell
43,327
-1,079,980
-96% -$4.95M ﹤0.01% 5317
2024
Q1 		$6.09M Buy
1,123,307
+1,119,766
+31,623% +$8.04M ﹤0.01% 2925
2023
Q4 		$19.2K Hold
3,541
– – ﹤0.01% 6260
2023
Q3 		$31.2K Buy
+3,541
New +$47.1K ﹤0.01% 5953

Other funds holding SGMT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

JP Morgan Chase's SGMT Position: Q2 2026 in Review

JP Morgan Chase increased its Sagimet Biosciences (SGMT) stake by 1,148% in Q2 2026, buying an estimated $181K and bringing the position to 28,930 shares worth $225K. The position accounts for ﹤0.01% of the portfolio, ranked #5555.

JP Morgan Chase first reported a position in SGMT in Q3 2023 and has held it in 12 quarters since. The position peaked at $6.09M in Q1 2024. 122 funds tracked by Wall St. Rank hold SGMT as of Q2 2026.

  • JP Morgan Chase held 28,930 shares of Sagimet Biosciences worth $225K as of Q2 2026.
  • JP Morgan Chase bought 26,612 Sagimet Biosciences shares in Q2 2026, an estimated $181K.
  • Sagimet Biosciences made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #5555 holding.
  • JP Morgan Chase first reported a position in Sagimet Biosciences in Q3 2023 and has held it in 12 quarters since.
  • JP Morgan Chase's Sagimet Biosciences position peaked at $6.09M in Q1 2024.
  • 122 funds tracked by Wall St. Rank held Sagimet Biosciences as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.